According to Brean Murray Carret, Inhibitex INHX target price is raised to $26.
Brean Murray Carret said that Bristol-Myers Squibb and Inhibitex announced an agreement under which BMS will acquire all outstanding shares of Inhibitex for $26 per share or approximately $2.5 billion.
Inhibitex closed on Friday at $9.87.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in